Sodium-glucose cotransporter 2 inhibitor

Phase 3Small molecule

Sodium-glucose cotransporter 2 inhibitor is one of 118 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Heart FailureActive, not recruiting

NephropathyRecruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Heart FailurePreclinical

Active, not recruiting

NephropathyPhase 3

Recruiting

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Sodium-glucose cotransporter 2 inhibitor

MMayo Clinic

Phase 3

2 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Amidate

Pfizer

Preclinical

1 6

Activase

Zemplar

Adriamycin

Savaysa

Xifaxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Post-ApprovalRecruiting

Nephropathy

NCT04662723

Clinical

Trials by Indication[1]

Heart Failure2 trials

Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure

Unknown status·—··NCT06137430·98 enrolled

Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure

Unknown status·QQueen's University, Belfast··NCT06140251·68 enrolled

Nephropathy1 trial

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

Recruiting·FFondazione Schena·Phase 4·NCT04662723·878 enrolled

Cardiovascular Disease1 trial

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Completed·MMayo Clinic··NCT05214573·386,301 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Sodium-glucose cotransporter 2 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium-glucose cotransporter 2 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodium-glucose cotransporter 2 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMayo Clinic

Sodium-glucose cotransporter 2 inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Heart Failure2 trials

Nephropathy1 trial

Cardiovascular Disease1 trial

References

Drug Info

Quick Facts

Related News